Genentech, Inc.

Hoffmann-la Roche Inc.

Abbvie Inc.

F. Hoffmann-la Roche Ag

University of Texas System

Deepak Sampath

Michelle Nannini

Christian Klein

Wayne J Fairbrother

Jeffrey Wallin

Lori Friedman

Marcia Belvin

Kui Lin

Elizabeth Punnoose

John F Seymour

Andrew W Roberts

Rod A Humerickhouse

Sari L Heitner Enschede

Mallika Singh

Klaus Hoeflich

Premal Patel

Sonal Patel

Leisa Johnson

Ulka Vijapurkar

Nicholas D Smith

Edna Chow Maneval

Mark Merchant

Gail Lewis Phillips

Ingrid Wertz

Debasish F Roychowdhury

Marina Konopleva

James David Joseph

Jing Qian

Brian Lee

Jeffrey J Hager

Lina Han

Kyle Edgar

Kyung Song

Marina Yurievna Konopleva

Timothy Wilson

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor

The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer

The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.

Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor

The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R, R, R, R, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use

Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.

Methods and compositions for modulating estrogen receptor mutants

The invention provides combinations comprising a) compound of formula I: (formula I), or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer. 

Combinations of AKT and MEK inhibitor compounds, and methods of use

The invention provides A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.

Combinations of AKT inhibitor compounds and erlotinib, and methods of use

The invention provides a combination of a) a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer. 

Combinations of AKT inhibitor compounds and abiraterone, and methods of use

The invention provides A combination of, a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer. 

Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents. 

Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Growing community of inventors

South San Francisco, CA, United States of America

Deepak Sampath